
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
ARMCX1 CRISPR Activation Plasmid (h) | sc-407214-ACT | 20 µg | $397.00 | |||
ARMCX1 CRISPR Activation Plasmid (h2) | sc-407214-ACT-2 | 20 µg | $397.00 |
ARMCX1 (armadillo repeat-containing, X-linked 1) encodes a mitochondria-associated armadillo repeat protein implicated in regulating mitochondrial trafficking, dynamics, and quality control in a cell type–dependent manner. Through interactions with cytoskeletal and organelle positioning machinery, ARMCX1 has been linked to processes such as neurite outgrowth, cellular stress responses, and maintenance of mitochondrial homeostasis. Altered ARMCX family activity has been associated with dysregulated apoptosis, metabolic remodeling, and changes in cell motility, making ARMCX1 relevant to studies of neurobiology and cancer-related phenotypes. As an X-linked gene, ARMCX1 also provides a useful context for investigating sex-biased regulation and dosage effects in human cell models.
ARMCX1 CRISPR Activation Plasmid (h) provides a targeted, non-destructive approach to upregulating endogenous ARMCX1 expression without altering the underlying DNA sequence.
ARMCX1 CRISPR Activation Plasmid (h) is a three-plasmid synergistic activation mediator (SAM) system engineered for highly efficient, site-specific transcriptional upregulation of the ARMCX1 locus in human cell lines. The system is built around a catalytically inactive Cas9 (dCas9) carrying two inactivating mutations (D10A and N863A) that eliminate nuclease activity while preserving DNA binding. This dCas9 is fused to VP64, a potent transcriptional activator, and is co-expressed with a blasticidin resistance gene for selection. The second plasmid encodes the MS2-p65-HSF1 fusion protein, a secondary activator complex that works in concert with dCas9-VP64, alongside a hygromycin resistance gene. The third plasmid encodes a target-specific 20 nt sgRNA fused to two MS2 RNA aptamers that recruit the MS2-p65-HSF1 complex to the activation site, accompanied by a puromycin resistance gene. The three plasmids are delivered at a 1:1:1 mass ratio for balanced expression of all system components.
Once assembled at the target locus, the SAM complex binds within approximately 200 bp upstream of the ARMCX1 transcriptional start site, where VP64, p65, and HSF1 act in concert to recruit transcriptional machinery and drive upregulation of endogenous ARMCX1 expression. Unlike nuclease-active Cas9, dCas9 does not introduce double-strand breaks or modify the genomic sequence, preserving the native ARMCX1 locus and enabling the study of ARMCX1-dependent transcriptional responses at the endogenous locus, making it a valuable tool for functional studies, target gene identification, and the modeling of ARMCX1 pathway restoration in tumor cells with silenced or reduced ARMCX1 expression.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.